ReviewInternational urology and nephrology2022
COVID-19 and the kidney: time to take a closer look.
Review in International urology and nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Metabolic score for visceral fat profiles and incident cardiovascular disease in adults with CKM syndrome stages 0-3: a CHARLS longitudinal study.BMC cardiovascular disorders · 2026Article
- Association between hypertension and risk of respiratory failure and mortality in patients with COVID-19: a retrospective cohort study with predictive model development.Frontiers in medicine · 2026Article
- Impact of COVID-19 on chronic kidney disease progression in non-dialysis patients: a retrospective cohort study in Palestine.Annals of medicine · 2025Article
- Observational
- Protective Effects of Liposomal Vitamin C on SARS-CoV-2 Target Viral Entry Genes in Renal Cells.Reports of biochemistry & molecular biology · 2025Article
- Lithium in the time of COVID: forever vigilant.International journal of bipolar disorders · 2024Article
- The impact of hypertension on clinical manifestations of Omicron variant BA.1 infection in adult patients.Microbiology spectrum · 2024Article
- Assessing the Diagnostic Values of the Neutrophil-to-Lymphocyte Ratio (NLR) and Systematic Immunoinflammatory Index (SII) as Biomarkers in Predicting COVID-19 Severity: A Multicentre Comparative Study.Medicina (Kaunas, Lithuania) · 2024Article
- Using National COVID cohort collaborative (N3C) data to explore impact of COVID-19 infection on kidney function in patients receiving lithium therapy.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- COVID-19 and Multiorgan Response: The Long-Term Impact.Current problems in cardiology · 2023Review
- Long-term interplay between COVID-19 and chronic kidney disease.International urology and nephrology · 2023Review
- Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity.Antibodies (Basel, Switzerland) · 2023Article
- Association of serum vitamin D concentration with the final course of hospitalization in patients with COVID-19.Frontiers in immunology · 2023Article
- Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease.Frontiers in immunology · 2023Article
- The role of kidney injury biomarkers in COVID-19.Renal failure · 2022Review
- The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.JMIR public health and surveillance · 2022Observational
- Renal, cardiac, neurological, cutaneous and coagulopathic long-term manifestations of COVID-19 after recovery; A review.Epidemiology and infection · 2022Review
- Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service.Biomolecules · 2022Article
- Predictors of Mortality in Adults with Acute Kidney Injury Requiring Dialysis: A Cohort Analysis.International journal of nephrology · 2022Article
- Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although coronavirus disease (COVID-19) is primarily a respiratory disease, the kidney may be among the target organs of infection with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Independently of baseline kidney function, acute kidney injury (AKI) is a common complication of COVID-19, associated with increased mortality and morbidity. Most frequently, COVID-19 causes acute tubular necrosis; however, in some cases, collapsing focal segmental glomerulosclerosis and direct viral tropism of the kidneys have also been documented. AKI secondary to COVID-19 has a multi-factorial origin. Even mild impairment of renal function is an independent risk factor for COVID-19 infection, hospitalisation and mortality. Dialysis patients also carry an increased risk of other severe COVID-related complications, including arrhythmias, shock, acute respiratory distress syndrome and acute heart failure. In such patients, COVID-19 may even present with atypical clinical symptoms, including gastrointestinal disorders and deterioration of mental status. More research is needed on the exact effects of SARS-CoV-2 on the kidneys. Finally, it remains to be proven whether the outcome of patients with kidney disease may be improved with anticipated vaccination programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.